ELF shows how it grows a portfolio for the future

22 February 2018

The European Lead Factory has been continuously recruiting high quality target programmes over the past years. With a clear infographic, the European Lead Factory makes the process of growing its portfolio visible.

Only in 2014, ELF delivered the first hits to target owners to further advance their early stage drug discovery programmes. At the turn of the year 2016/2017, two and a half years later, three programmes proved to be worth investing in, e.g. Margit Mahlapuu’s by GU Ventures, Christopher Schofield’s by ENABLE and Richard Mead’s by Parkinson’s UK. Currently, the crowdsourced portfolio contains over 80 drug discovery programmes, distributed among all relevant therapeutic areas, with 40% in the area of oncology, followed by 25% in infectious diseases and 15% in CNS & neurology.

The major impact of the portfolio and opportunities for investment and translating the ELF results towards the clinic are to be expected in the upcoming years, with ELF becoming a platform full of potential.

Interested in the ELF portfolio? Click here